STAA - Gunggunge utang jangka dawa STAAR Surgical Co.

STAA has significant pricing power thanks to its innovative EVO implants for myopia, as evidenced by the current stock price on GURU.Markets, visualized below. The business combines the protective benefits of medicine with the volatility of aesthetic procedures, and its long-term debt amounts to 0.03. Stable management is focused on expansion in Asia, ensuring high margins and shareholder confidence.

This indicator aggregates total long-term credit obligations, updating data daily to eliminate time gaps between quarterly reports and to assess solvency. By monitoring the value of the firm's long-term borrowings, an investor determines the degree of financial risk; for STAAR Surgical Company (STAA), moderate leverage is critical during the aggressive expansion of its market share in implantable lenses, which are displacing laser vision correction.